RaySearch Laboratories invites you to join our webinar community!
Here, industry experts have a platform to share insights, express innovative ideas, and engage in active discussions – where every voice counts in shaping the future of advanced cancer care.
RAYSEARCH WEBINARS: ADVANCING REIRRADIATION SERIES
🔥Episode 1: Reirradiation in RayStation®: Planning with cumulative EQD2 in 3D**
Together with experts from RaySearch and Leeds Teaching Hospitals NHS Trust, we explored how the upcoming RayStation®* version supports cumulative EQD2 evaluation and optimization for reirradiation planning**, including clinical case demonstrations** and a lively Q&A session.
📽️ For those who were unable to attend, you can watch the recording here.
📖 We have also compiled all questions raised during the webinar and their corresponding answers, which you can access here.
🔥 Stay tuned for the next episode in the series!
*Subject to regulatory clearance in some markets.
**This functionality is investigational, not CE marked or FDA cleared, and is not available for clinical use.
Fullscreen here.
Our goal is to provide essential context, address critical questions, and ensure the trusted and seamless integration of our developed solutions into clinical workflows while building shared understanding in the community.
It all started simply – with a question.
In 2022, RaySearch asked the Help Ukraine Group (HUG) how a company developing cancer care software could support cancer patients in Ukraine.
Since then, 10 cancer centers across Ukraine and Taras Shevchenko National University of Kyiv have received donations from RaySearch – 20 RayStation treatment planning systems in total.
At ESTRO 2025, RaySearch invited Ruslan Zelinskyi and Serhii Brovchuk to present the current state of radiotherapy in Ukraine – and, more importantly, to help answer another question: What more can we do for Ukraine’s cancer care field?
Get you answers and watch the presentation here.
Become part of RaySearch Webinars, our expertise-driven community. Only by learning together can we effectively lead, paving the way toward a future where cancer has ended.
